Dan Leonard
Stock Analyst at UBS
(4.09)
# 525
Out of 5,113 analysts
310
Total ratings
57.39%
Success rate
10.7%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGEN Repligen | Maintains: Buy | $190 → $200 | $163.63 | +22.23% | 1 | Jan 16, 2026 | |
| IQV IQVIA Holdings | Maintains: Buy | $250 → $280 | $241.04 | +16.16% | 18 | Jan 8, 2026 | |
| A Agilent Technologies | Maintains: Buy | $170 → $180 | $135.95 | +32.40% | 23 | Nov 25, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $13 → $14 | $21.62 | -35.25% | 7 | Nov 7, 2025 | |
| TECH Bio-Techne | Maintains: Buy | $65 → $70 | $68.23 | +2.59% | 12 | Nov 6, 2025 | |
| BRKR Bruker | Maintains: Neutral | $40 → $43 | $47.67 | -9.80% | 12 | Nov 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $80 → $110 | $114.59 | -4.01% | 11 | Oct 30, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Neutral | $500 → $590 | $623.91 | -5.44% | 18 | Oct 23, 2025 | |
| EXAS Exact Sciences | Maintains: Neutral | $61 → $53 | $102.34 | -48.21% | 10 | Aug 7, 2025 | |
| CERT Certara | Maintains: Buy | $18 → $15 | $9.68 | +54.96% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $300 → $305 | $602.54 | -49.38% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $225 | $235.75 | -4.56% | 18 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1,530 → $1,350 | $1,425.18 | -5.28% | 9 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $297.71 | +4.13% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $299.70 | +3.44% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $114.61 | +0.34% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $94.10 | +5.21% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $11.65 | +114.59% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 → $185 | $219.53 | -15.73% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $10.23 | -12.02% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $27.27 | +28.35% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $152.09 | +31.50% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $3.80 | +189.86% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $240.34 | -70.87% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $19.23 | -63.60% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $390.09 | -11.56% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $187.99 | +38.31% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $184.24 | -21.30% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $75.20 | +19.68% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $59 → $61 | $54.22 | +11.80% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $271.12 | +25.41% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $16.97 | +41.43% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $5.92 | +491.22% | 12 | Aug 14, 2019 |
Repligen
Jan 16, 2026
Maintains: Buy
Price Target: $190 → $200
Current: $163.63
Upside: +22.23%
IQVIA Holdings
Jan 8, 2026
Maintains: Buy
Price Target: $250 → $280
Current: $241.04
Upside: +16.16%
Agilent Technologies
Nov 25, 2025
Maintains: Buy
Price Target: $170 → $180
Current: $135.95
Upside: +32.40%
10x Genomics
Nov 7, 2025
Maintains: Neutral
Price Target: $13 → $14
Current: $21.62
Upside: -35.25%
Bio-Techne
Nov 6, 2025
Maintains: Buy
Price Target: $65 → $70
Current: $68.23
Upside: +2.59%
Bruker
Nov 4, 2025
Maintains: Neutral
Price Target: $40 → $43
Current: $47.67
Upside: -9.80%
Guardant Health
Oct 30, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $114.59
Upside: -4.01%
Thermo Fisher Scientific
Oct 23, 2025
Maintains: Neutral
Price Target: $500 → $590
Current: $623.91
Upside: -5.44%
Exact Sciences
Aug 7, 2025
Maintains: Neutral
Price Target: $61 → $53
Current: $102.34
Upside: -48.21%
Certara
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $9.68
Upside: +54.96%
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $602.54
Upside: -49.38%
Jul 23, 2025
Maintains: Buy
Price Target: $240 → $225
Current: $235.75
Upside: -4.56%
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,425.18
Upside: -5.28%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $297.71
Upside: +4.13%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $299.70
Upside: +3.44%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $114.61
Upside: +0.34%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $94.10
Upside: +5.21%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $11.65
Upside: +114.59%
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $219.53
Upside: -15.73%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $10.23
Upside: -12.02%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $27.27
Upside: +28.35%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $152.09
Upside: +31.50%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $3.80
Upside: +189.86%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $240.34
Upside: -70.87%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $19.23
Upside: -63.60%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $390.09
Upside: -11.56%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $187.99
Upside: +38.31%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $184.24
Upside: -21.30%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $75.20
Upside: +19.68%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $59 → $61
Current: $54.22
Upside: +11.80%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $271.12
Upside: +25.41%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $16.97
Upside: +41.43%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $5.92
Upside: +491.22%